Want to see HK:2256 full AI Analyst Report?
Top Page
Abbisko Cayman Limited
(2256)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$6.50
▼(-50.08% Downside)
Action:Reiterated
Date:10/31/26
The score is held up by improving fundamentals and a relatively strong balance sheet (low leverage and positive 2025 profitability/cash flow), but is dragged down by a clearly bearish technical setup (price below all major moving averages and negative MACD) and limited valuation clarity due to a negative P/E and no dividend yield data.
Positive Factors
Conservative leverage
Low leverage relative to equity gives Abbisko greater financial flexibility over the next several quarters. The sizable equity base can help absorb operating volatility and preserve capacity to fund the business without relying heavily on additional borrowing.
Negative Factors
Revenue contraction
The return to negative revenue growth raises concern that the company has not yet established a consistently expanding commercial base. A sustained slowdown could limit operating leverage, reduce reinvestment capacity, and make future profitability more dependent on cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Low leverage relative to equity gives Abbisko greater financial flexibility over the next several quarters. The sizable equity base can help absorb operating volatility and preserve capacity to fund the business without relying heavily on additional borrowing.
Read all positive factors
Abbisko Cayman Limited (2256) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.50B
Dividend YieldN/A
Average Volume (3M)1.30M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-83.32%
EPS Growth-383.82%
CountryHK
Employees286
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding726,205,300
10 Day Avg. Volume1,587,611
30 Day Avg. Volume1,304,873
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)3.79
Price to Sales (P/S)12.24
P/FCF Ratio98.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$24.25Price Target Upside86.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)HK$236.72M
Abbisko Cayman Limited Business Overview & Revenue Model
Company Description
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeuti...
Abbisko Cayman Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
73
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 97.27M | 596.28M | 503.99M | 19.06M | 0.00 | 22.68M |
| Gross Profit | 95.50M | 596.28M | 503.99M | 19.06M | 0.00 | 22.68M |
| EBITDA | -502.25M | 49.50M | 1.98M | -410.99M | -481.39M | -1.80B |
| Net Income | -466.69M | 53.82M | 28.30M | -431.58M | -498.29M | -1.81B |
Balance Sheet | ||||||
| Total Assets | 2.70B | 2.35B | 2.11B | 2.12B | 2.49B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.45B | 2.10B | 2.01B | 1.96B | 2.35B | 2.57B |
| Total Debt | 454.73M | 303.61M | 24.29M | 35.72M | 45.58M | 53.80M |
| Total Liabilities | 515.26M | 430.41M | 148.71M | 134.28M | 143.16M | 118.48M |
| Stockholders Equity | 2.18B | 1.92B | 1.96B | 1.98B | 2.35B | 2.54B |
Cash Flow | ||||||
| Free Cash Flow | -336.19M | 73.75M | -20.32M | -456.98M | -366.64M | -182.08M |
| Operating Cash Flow | -334.49M | 79.29M | -12.92M | -444.73M | -343.90M | -169.74M |
| Investing Cash Flow | -15.24M | 211.94M | -196.50M | 378.52M | -216.57M | -1.46B |
| Financing Cash Flow | 441.93M | 186.89M | -80.86M | -16.11M | -20.81M | 2.10B |
Abbisko Cayman Limited Technical Analysis
Negative
13.02
Price Trends
8.43
Negative
9.34
Negative
10.87
Negative
Market Momentum
-0.63
Positive
23.05
Positive
3.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Negative. The current price of 13.02 is above the 20-day moving average (MA) of 7.54, above the 50-day MA of 8.43, and above the 200-day MA of 10.87, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 23.05 is Positive, neither overbought nor oversold. The STOCH value of 3.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2256.
Abbisko Cayman Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
53 Neutral | HK$4.50B | -7.07 | -22.75% | ― | -83.32% | -383.82% | |
52 Neutral | HK$925.48M | -2.35 | -66.16% | ― | 67.48% | 43.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$6.32B | -56.20 | -9.45% | ― | 68.12% | 81.84% | |
47 Neutral | HK$6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:2256
Abbisko Cayman Limited
6.19
-8.37
-57.49%
HK:9966
Alphamab Oncology
6.22
-5.29
-45.96%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.32
-42.59%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.22
-1.26
-36.21%
HK:2171
CARsgen Therapeutics Holdings Ltd.
10.63
-5.85
-35.50%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.79
-29.76%
Abbisko Cayman Limited Corporate Events
Abbisko’s Achondroplasia Drug Wins EMA Orphan Status, Advancing Global Push
Oct 21, 2026
Abbisko Cayman Limited said its subsidiary Abbisko Therapeutics has received Orphan Designation from the European Medicines Agency for lavengratinib (ABSK061), an orally available FGFR2/3 inhibitor for treating achondroplasia. The rare, life‑...
Abbisko Therapeutics Posts Encouraging Phase II Data for Pediatric Achondroplasia Drug
Sep 21, 2026
Abbisko Therapeutics has reported positive preliminary Phase II data for its FGFR2/3 inhibitor lavengratinib (ABSK061) in children aged six and above with achondroplasia. In the lowest-dose cohort, seven participants treated once daily for 27 week...
Abbisko Shareholders Back Name Change to Abbisko Medicine Co., Ltd.
Sep 17, 2026
Abbisko Cayman Limited, a Hong Kong-listed biopharmaceutical company incorporated in the Cayman Islands, is repositioning its corporate identity around its core medicine business. With an executive and independent board chaired by Dr. Xu Yao-Chang...
Abbisko Therapeutics Begins First-in-Human Trial of Novel Pan-KRAS Cancer Drug ABSK211
Aug 31, 2026
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has commenced first patient dosing in a Phase I clinical trial of ABSK211, an oral, highly potent small-molecule pan-KRAS inhibitor. The study targets patients with advanced solid tumor...
Abbisko Seeks Shareholder Approval to Rebrand as Abbisko Medicine Co., Ltd.
Aug 28, 2026
Abbisko Cayman Limited has called an extraordinary general meeting to seek shareholder approval for a change of its English name to Abbisko Medicine Co., Ltd., along with a corresponding change to its dual foreign Chinese name. The meeting will be...
Abbisko Cayman Advances Oncology Pipeline as Lead Drug Pimicotinib Launches in China
Aug 24, 2026
Abbisko Cayman Limited reported substantial operational progress for the six months ended June 30, 2026, highlighted by the commercial launch in China of its lead asset pimicotinib for tenosynovial giant cell tumor through a strategic partnership ...
Abbisko Proposes Rebrand to Abbisko Medicine Co., Ltd. Without Impact on Trading
Aug 24, 2026
Abbisko Cayman Limited plans to change its English name to Abbisko Medicine Co., Ltd., and adopt a new corresponding Chinese name, subject to shareholder approval at an extraordinary general meeting and the issuance of a new certificate of incorpo...
Abbisko Wins China IND Nod for Pan-KRAS Cancer Drug ABSK211
Aug 19, 2026
Abbisko Therapeutics has secured Investigational New Drug clearance from China’s National Medical Products Administration for ABSK211, an oral small-molecule pan-KRAS inhibitor intended for patients with advanced solid tumors harboring KRAS ...
Abbisko Sets August Board Meeting to Approve Interim Results and Weigh Dividend
Aug 3, 2026
Abbisko Cayman Limited has scheduled a board meeting for August 24, 2026 to review and approve its unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recomm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.